It is of particular interest to note that the pro-tumor role of wild-type IDH2 and its underlying mechanisms are different from the oncogenic function of IDH2 mutations, which are most often observed in certain gliomas and leukemia, such as acute myeloid leukemia (AML) [30,31]. The gene discussed is IDH2; the disease is central nervous system cancer.